Jeff Kearns

Company: Novartis AG

Job title: Director

Seminars:

QSP Modeling of a Transiently Inactivating ADC Highlights Benefit of Short Antibody Half Life 10:00 am

Reviewing a case study of a targeted ADC with transiently inactivating payload Understanding the impact of decoupled antibody and payload kinetics on modeling and bioanalytical strategies Evaluating MID3 approaches for design to human dose prediction for targeted ADCsRead more

day: Conference Day 1